| dc.contributor.author | Fisher, David W. | |
| dc.contributor.author | Tchoula Tchokonte, Moise B. | |
| dc.contributor.author | Dube, Admire | |
| dc.contributor.author | Mhambi, Sinaye | |
| dc.date.accessioned | 2021-10-01T09:46:07Z | |
| dc.date.available | 2021-10-01T09:46:07Z | |
| dc.date.issued | 2021 | |
| dc.identifier.citation | Mhambi, Sinaye & Fisher, David & Tchokonte, Moise & Dube, Admire. (2021). Permeation Challenges of Drugs for Treatment of Neurological Tuberculosis and HIV and the Application of Magneto-Electric Nanoparticle Drug Delivery Systems. Pharmaceutics. 13. 1479. 10.3390/pharmaceutics13091479. | en_US |
| dc.identifier.issn | 19994923 | |
| dc.identifier.uri | http://hdl.handle.net/10566/6851 | |
| dc.description | This research was funded by an award from the Fogarty International Center of the National Institutes of Health under Award Number K43TW010371 awarded to AD and funding from the National Research Foundation of South Africa (grant ID 109059) warded to AD. The South African National Nanoscience Postgraduate Teaching and Training Platform is also gratefully acknowledged. | en_US |
| dc.description.abstract | The anatomical structure of the brain at the blood-brain barrier (BBB) creates a limitation for the movement of drugs into the central nervous system (CNS). Drug delivery facilitated by magneto-electric nanoparticles (MENs) is a relatively new non-invasive approach for the delivery of drugs into the CNS. These nanoparticles (NPs) can create localized transient changes in the permeability of the cells of the BBB by inducing electroporation. MENs can be applied to deliver antiretrovirals and antibiotics towards the treatment of human immunodeficiency virus (HIV) and tuberculosis (TB) infections in the CNS. This review focuses on the drug permeation challenges and reviews the application of MENs for drug delivery for these diseases. We conclude that MENs are promising systems for effective CNS drug delivery and treatment for these diseases, however, further preclinical and clinical studies are required to achieve translation of this approach to the clinic. © 2021 by the authors. Licensee MDPI, Basel, Switzerland | en_US |
| dc.description.sponsorship | National Nanoscience Postgraduate Teaching and Training Platform
National Institutes of Health (NIH): ID K43TW010371
Fogarty International Center (FIC)
National Research Foundation (NRF): ID 109059 | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | MDPI | en_US |
| dc.subject | Blood-brain barrier | en_US |
| dc.subject | Infectious diseases | en_US |
| dc.subject | Central nervous system | en_US |
| dc.subject | CNS | en_US |
| dc.subject | Electroporation | en_US |
| dc.subject | Drug delivery system | en_US |
| dc.subject | Magneto-electric | en_US |
| dc.subject | Nanoparticles | en_US |
| dc.subject | Tuberculosis (TB) | en_US |
| dc.subject | Neurological disorders | en_US |
| dc.subject | HIV | en_US |
| dc.title | Permeation challenges of drugs for treatment of neurological tuberculosis and HIV and the application of magneto-electric nanoparticle drug delivery systems | en_US |
| dc.type | Article | en_US |
